-

Zoetis to Participate in the 39th Annual J.P. Morgan Healthcare Conference

PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) will participate in the 39th Annual J.P. Morgan Healthcare Conference on Monday, Jan. 11, 2021. Kristin Peck, Chief Executive Officer, will represent the company and respond to questions from analysts. She is scheduled to present at 10:00 a.m. ET.

Investors and other interested parties will be able to access a live audio webcast of the virtual presentation by visiting http://investor.zoetis.com/events-presentations. A replay of the presentation will also be available on the Zoetis website at the conclusion of the event.

About Zoetis

Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 65 years of experience in animal health, Zoetis discovers, develops, manufactures and commercializes medicines, vaccines and diagnostic products, which are complemented by biodevices, genetic tests and precision livestock farming. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2019, the company generated annual revenue of $6.3 billion with approximately 10,600 employees. For more information, visit www.zoetis.com.

ZTS-COR
ZTS-IR

Contacts

Media Contacts:
Bill Price
1-973-443-2742 (o)
william.price@zoetis.com

Kristen Seely
1-973-443-2777 (o)
kristen.seely@zoetis.com

Investor Contacts:
Steve Frank
1-973-822-7141 (o)
steve.frank@zoetis.com

Keith Gaub
1-973-822-7154 (o)
keith.gaub@zoetis.com

Zoetis Inc.

NYSE:ZTS

Release Summary
Zoetis to present at the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021.
Release Versions
$Cashtags

Contacts

Media Contacts:
Bill Price
1-973-443-2742 (o)
william.price@zoetis.com

Kristen Seely
1-973-443-2777 (o)
kristen.seely@zoetis.com

Investor Contacts:
Steve Frank
1-973-822-7141 (o)
steve.frank@zoetis.com

Keith Gaub
1-973-822-7154 (o)
keith.gaub@zoetis.com

Social Media Profiles
More News From Zoetis Inc.

Zoetis Receives FDA Approval for Convenia® RTU for Dogs (cefovecin injectable suspension), Helping More Medium and Large Dogs Access Single-Injection Treatment

PARSIPPANY, N.J.--(BUSINESS WIRE)--Convenia RTU for Dogs provides up to 14 days of antibiotic treatment in a single dose for susceptible bacterial skin infections...

Zoetis Appoints Iris Knobloch to its Board of Directors

PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) today announced the appointment of Iris Knobloch to its Board of Directors, effective as of December 1, 2026. With decades of experience across global media and consumer businesses, Ms. Knobloch brings a distinct combination of international leadership, proven public company board experience across financial services, hospitality and media, and deep consumer and digital expertise to the Zoetis Board. She currently serves on the boards of...

Zoetis Declares Fourth Quarter 2026 Dividend

PARSIPPANY, N.J.--(BUSINESS WIRE)--The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.53 per share for the fourth quarter of 2026. The dividend will be paid on Tuesday, December 1, 2026, to all holders of record of the Company’s common stock as of the close of business on Friday, October 30, 2026. About Zoetis Zoetis is the world’s leading animal health company, driven by a singular purpose: to nurture our world and humankind by advancing care for animals. With a leg...
Back to Newsroom